Free Newsletter
House passes reform bill. What next?
Healthcare reform is a reality. Passed by the House with a 219-212 vote, the bill now goes to President Obama for signing within the next few days. And to complete the package, a bill of negotiated changes to the newly passed reform legislation will go to the Senate for a vote.
The reform package will extend insurance coverage to some 32 million more Americans, adding millions more paying customers into the healthcare system. That's expected to be a big bonus for drugmakers: Goodbye to postponed refills and never-filled prescriptions. Hello to better treatment--and higher drug sales--for the newly insured.
But while drugmakers have good reason to rejoice, there's still some opposition to the bill. So we can look for an extended public relations effort from the White House, which will highlight new coverage and other changes as they go into effect. And you can bet that all eyes will be watching how this bill is implemented; there won't be much tolerance for mistakes. In other words, the healthcare-reform saga isn't over yet.
- get more from the New York Times
- see the Washington Post piece
- read the Wall Street Journal story
Related Articles:
Number of unfilled scrips approaches 15%
Healthcare reform nears House vote
The scramble to save PhRMA's $80B deal
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: